Innovent Starts Phase I Trial of CD47/PD-L1 Bispecific for Solid Tumor Cancers

Suzhou Innovent dosed the first patient in a China Phase I clinical trial of its anti-CD47/PD-L1 bispecific antibody in patients with advanced malignancies. The trial is designed to evaluate the safety, tolerability and initial anti-tumor efficacy of IBI322 in patients with lung, cervical, esophageal, head and neck squamous cell and liver carcinomas who have failed standard therapy. IBI322, which has the potential to be a first-in-class drug, is approved to start testing in both the US and China. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //